Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?

Anna Wankowicz-Kalinska, Caroline Le Poole, Rene Van Den Wijngaard, Walter J. Storkus, Pranab K. Das*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.

Original languageEnglish (US)
Pages (from-to)254-260
Number of pages7
JournalPigment Cell Research
Issue number3
StatePublished - Jun 2003


  • Antibodies
  • Melanoma
  • T cells
  • Vitiligo

ASJC Scopus subject areas

  • Agronomy and Crop Science
  • Plant Science
  • Clinical Biochemistry
  • Cell Biology
  • Developmental Biology


Dive into the research topics of 'Melanocyte-specific immune response in melanoma and vitiligo: Two faces of the same coin?'. Together they form a unique fingerprint.

Cite this